WO2021210632A1 - アデノウイルスの免疫測定方法及び免疫測定器具 - Google Patents

アデノウイルスの免疫測定方法及び免疫測定器具 Download PDF

Info

Publication number
WO2021210632A1
WO2021210632A1 PCT/JP2021/015540 JP2021015540W WO2021210632A1 WO 2021210632 A1 WO2021210632 A1 WO 2021210632A1 JP 2021015540 W JP2021015540 W JP 2021015540W WO 2021210632 A1 WO2021210632 A1 WO 2021210632A1
Authority
WO
WIPO (PCT)
Prior art keywords
adenovirus
antibody
antigen
monoclonal antibody
immunoassay
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2021/015540
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
恭 宮澤
三和 桑原
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denka Co Ltd
Original Assignee
Denka Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denka Co Ltd filed Critical Denka Co Ltd
Priority to US17/919,065 priority Critical patent/US20230176055A1/en
Priority to KR1020227035454A priority patent/KR20220167285A/ko
Priority to EP21788631.6A priority patent/EP4116323A4/en
Priority to CN202180028573.3A priority patent/CN115362170A/zh
Publication of WO2021210632A1 publication Critical patent/WO2021210632A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to an immunoassay method and an immunoassay instrument for adenovirus, and an anti-adenovirus antibody for that purpose.
  • Adenoviruses include respiratory diseases such as acute febrile throat, pharyngeal conjunctivitis, acute airway inflammation, and viral pneumonia, eye diseases such as acute follicular conjunctivitis and epidemic keratoconjunctivitis, digestive diseases such as infectious gastroenteritis, and urinary tract. It is known as a pathogen for urinary diseases such as inflammation.
  • adenoviruses are classified into 7 types, A to G, and there are more than 80 types. Up to type 51 was reported as a serotype, but after type 52, it was reported as a genotype based on the determination of the entire base sequence (Non-Patent Document 1).
  • adenovirus When adenovirus infects humans, it exhibits a variety of clinical symptoms and there are few specific medical conditions, so it is difficult to prove adenovirus infection from clinical symptoms. In addition, adenovirus is highly infectious, and it is necessary to prove the virus infection at an early stage in order to prevent outbreaks.
  • an immunochromatography method using an anti-adenovirus antibody and a method using EIA have been developed, but the positive rate in the ophthalmic field where the amount of sample that can be collected is small is 60. % Or less, and a more sensitive rapid diagnostic method or an anti-adenovirus monoclonal antibody that can be used for this is required.
  • Non-Patent Document 2 In the outbreak trend survey of the National Institute of Infectious Diseases, patient outbreak information of pharyngoconjunctival fever, infectious gastroenteritis, and epidemic keratoconjunctivitis is grasped as adenovirus-related diseases. Acute respiratory disease, pharyngoconjunctival fever caused by B, C, E adenovirus, infectious gastroenteritis caused by A, F, G adenovirus, epidemic keratoconjunctivitis caused by B, D, E adenovirus Known as (Non-Patent Document 2).
  • Type B adenovirus type 3 and type E adenovirus type 4 are the most common etiologies of epidemic keratoconjunctivitis and pharyngeal conjunctivitis. It is also the cause of epidemic keratoconjunctivitis outbreaks in other countries, especially in East and Southeast Asia.
  • Adenovirus types 8, 19 and 37 are well known epidemiological causes of nosocomial infections. Recently, nosocomial infections caused by adenovirus have become an important social problem in public health, and have become an economic and ethical problem in hospitals.
  • Patent Documents 1 and 2 Currently, multiple monoclonal antibodies that react with adenovirus have been produced and reported. For example, a method for detecting adenovirus using a monoclonal antibody that reacts with a specific subtype of adenovirus has been reported (Patent Documents 1 and 2).
  • the present invention provides a monoclonal antibody capable of rapidly, easily, and highly sensitively detecting and measuring adenovirus contained in a test sample, an immunoassay method for adenovirus using the monoclonal antibody, and an immunoassay instrument. The purpose is.
  • the present inventors are effective in using a monoclonal antibody having a specific amino acid sequence contained in adenovirus as an epitope in order to detect adenovirus with higher sensitivity.
  • the present invention was completed by finding that.
  • the present invention is as follows. [1] A monoclonal antibody or an antigen-binding fragment thereof that reacts with a polypeptide having the 21st to 944th sequences of the amino acid sequence shown in SEQ ID NO: 1. [2] The antigen-antibody reaction with a polypeptide having at least one range of sequences selected from the 21st to 131st, 266th to 412th, and 448 to 944th sequences of the amino acid sequence shown in SEQ ID NO: 1, according to [1]. Monoclonal antibody or antigen-binding fragment thereof.
  • Adenovirus immunoassay methods including. [6] The method according to [5], wherein the immunoassay method is a sandwich method, and the monoclonal antibody or an antigen-binding fragment thereof is used for at least one of a label and a solid phase. [7] An immunoassay instrument for adenovirus, which comprises the monoclonal antibody according to any one of [1] to [4] or an antigen-binding fragment thereof.
  • the present invention provides a monoclonal antibody capable of rapidly, easily, and highly sensitively detecting and measuring adenovirus contained in a test sample, an immunoassay method for adenovirus using the monoclonal antibody, and an immunoassay instrument. be able to.
  • the monoclonal antibody of the present invention or an antigen-binding fragment thereof reacts with the polypeptide having the 21st to 944th sequences of the amino acid sequence shown in SEQ ID NO: 1.
  • the amino acid sequence of SEQ ID NO: 1 is the sequence of the type 3 adenovirus GB strain hexone monomer protein (GenBank Accession No. AB330084.1) composed of 944 amino acid residues.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention has at least one range of sequences selected from positions 21 to 131, 266 to 412, and 448 to 944 of the amino acid sequence of SEQ ID NO: 1.
  • Antigen-antibody reaction with polypeptide The 132nd to 265th and 413th to 447th sequences of the amino acid sequence of SEQ ID NO: 1 are considered to be sequences with low conservation among adenovirus subtypes.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention is at least one range selected from positions 21 to 115, 266 to 385, and 451 to 944 of the amino acid sequence of SEQ ID NO: 1.
  • the monoclonal antibody or antigen-binding fragment thereof of the present invention comprises the amino acid sequences of SEQ ID NO: 1, 21-45, 56-115, 266-385, 451-485, 526-575.
  • Adenovirus can be detected with high sensitivity by using a monoclonal antibody or an antigen-binding fragment thereof that reacts with a polypeptide having an amino acid sequence in the above range.
  • the monoclonal antibody of the present invention or an antigen-binding fragment thereof has a basic structure consisting of a heavy chain and a light chain, and each of the heavy chain and the light chain has a variable region capable of specifically binding to an antigen.
  • V H refers to the variable region of the heavy chain
  • VL refers to the variable region of the light chain.
  • the variable regions of the heavy and light chains include the amino acid sequences of the complementarity determining regions (CDRs), ie, CDR1, CDR2 and CDR3, and framework regions (FR), respectively.
  • the variable region comprises 3 or 4 FRs (eg, FR1, FR2, FR3 and optionally FR4) with 3 CDRs.
  • the monoclonal antibody of the present invention includes a four-stranded antibody (eg, two light chains and two heavy chains), a recombinant antibody or a modified antibody (eg, a chimeric antibody, a humanized antibody, a human antibody, a CDR transplantation).
  • a recombinant antibody or a modified antibody eg, a chimeric antibody, a humanized antibody, a human antibody, a CDR transplantation.
  • Antibodies, primated antibodies, deimmunized antibodies, similar humanized antibodies, semi-antibodies, bispecific antibodies are included.
  • the class of the monoclonal antibody is not limited to IgG, and may be IgM or IgY.
  • the antigen-binding fragment of a monoclonal antibody is a fragment obtained by separating only the antigen-binding site of the monoclonal antibody, and is, for example, Fab, Fab', F (ab') 2 produced by a known method. , Single chain antibody (scFv) and other fragments with specific antigen binding properties.
  • the monoclonal antibody of the present invention uses a known immunological method, and is a complex or extract containing an adenovirus containing the above-mentioned specific amino acid sequence with which the monoclonal antibody of the present invention reacts with an antigen antibody, or the adenovirus or a combination thereof. It can be obtained by immunizing an immunized animal with a partial peptide and producing a hybridoma using the cells of the immunized animal.
  • the length of the peptide used for immunization is not particularly limited, but a peptide having 5 amino acids or more, more preferably 10 amino acids or more can be used as an immunogen.
  • the immunogen can also be obtained from a culture solution, but a DNA encoding an adenovirus antigen containing the above-mentioned specific amino acid sequence with which the monoclonal antibody of the present invention reacts with an antigen-antibody is incorporated into a plasmid vector and introduced into a host cell. It can also be obtained by expressing it.
  • the adenovirus antigen or a partial peptide thereof as an immunogen can be expressed as a fusion protein with a protein as exemplified below, and can be used as an immunogen after purification or as unpurified.
  • Glutathione S-transferase GST
  • MBP maltose-binding protein
  • TRX thioredoxin
  • Nus tag, S tag, HSV which are commonly used by those skilled in the art as "protein expression / purification tags" for producing fusion proteins.
  • Tags, FRAG tags, polyhistidine tags, etc. can be used. It is preferable that the fusion protein with these is used as an immunogen after cleaving the above-mentioned adenovirus antigen or a partial peptide portion thereof and a tag portion other than the above tag portion using a digestive enzyme, separating and purifying the protein.
  • a known immunoglobulin purification method can be used to purify the monoclonal antibody from ascites or culture supernatant.
  • a fractionation method by salting out using ammonium sulfate or sodium sulfate, a PEG fractionation method, an ethanol fractionation method, a DEAE ion exchange chromatography method, a gel filtration method and the like can be mentioned.
  • It can also be purified by an affinity chromatography method using a carrier to which any of protein A, protein G, and protein L is bound, depending on the immune animal species and the class of the monoclonal antibody.
  • adenovirus can be detected with extremely high sensitivity by using the above-mentioned monoclonal antibody or an antigen-binding fragment thereof.
  • monoclonal antibody means “monoclonal antibody or antigen-binding fragment thereof” unless it is clear from the context that this is not the case.
  • the detection of adenovirus is performed by immunomeasurement of adenovirus using the antigen-antibody reaction between the above-mentioned monoclonal antibody and the adenovirus in the sample.
  • a monoclonal antibody reacts with an adenovirus as an antigen-antibody, it means that the monoclonal antibody reacts specifically with the adenovirus.
  • “Specific” means that in a liquid system in which an antigen protein and a monoclonal antibody are mixed, the antibody does not cause an antigen-antibody reaction at a detectable level with a component other than the antigen protein, or some binding reaction or association reaction occurs. Even if it occurs, it means that the reaction is clearly weaker than the antigen-antibody reaction between the antibody and the antigen protein.
  • any method well known to those skilled in the art can be used as the immunoassay method, such as a competitive method, an agglutination method, a Western blotting method, an immunostaining method, and a sandwich method.
  • the sandwich method is preferable as the immunoassay method of the present invention.
  • the sandwich method itself is well known in the field of immunoassay, and can be performed by, for example, an immunochromatography method or an ELISA method. All of these sandwich methods themselves are well known, and the method of the present invention can be carried out by a well-known sandwich method except that the above-mentioned specific monoclonal antibody is used.
  • two types of antibodies that recognize antigens are used, but in the method of the present invention, at least one of these two types of antibodies is used. Either one is the monoclonal antibody of the present invention described above. Immobilized antibodies immobilized on a solid phase have a limited amount of antibody that can be immobilized per unit area. Therefore, in order to better achieve the object of the present invention of improving sensitivity, at least an immobilized antibody is used. It is preferable to use the monoclonal antibody of the present invention.
  • the single type of monoclonal antibody is used as a immobilized antibody and a labeled antibody. It is also possible to use the sandwich method.
  • any solid phase in which the antibody can be immobilized by a known technique can be used as the solid phase on which the antibody is immobilized.
  • a porous thin film (membrane) having a capillary action. Particulate matter, test tube, resin flat plate and other known substances can be arbitrarily selected.
  • an enzyme, a radioactive isotope, a fluorescent substance, a luminescent substance, colored particles, colloidal particles and the like can be used.
  • the lateral flow type immunoassay using a membrane is particularly preferable from the viewpoint of simplicity and speed of clinical examination.
  • the quantification or semi-quantification inevitably involves “measurement”, and is therefore included in the "measurement” in the present invention. That is, in the present invention, the "measurement" of immunoassay includes any of quantitative, semi-quantitative, and detection.
  • Example 1 Preparation of anti-adenovirus monoclonal antibody 1.
  • Preparation of adenovirus antigen Adenovirus was infected with sensitive mammalian cells, cultured for several days, and then the culture solution of the adenovirus-infected cells was inactivated by ultraviolet irradiation. I used the one.
  • anti-adenovirus monoclonal antibody 1 BALB / c mice were immunized with the adenovirus inactivating antigen of Adenovirus, and the spleen was removed from the mice bred for a certain period of time. A plurality of hybridoma cell lines producing anti-adenovirus antibodies were obtained by fusing with mouse myeloma cells (P3 ⁇ 63). The acquired cell line was intraperitoneally administered to pristane-treated BALB / c mice, and about 2 weeks later, antibody-containing ascites was collected. From the obtained ascites, IgG was purified by an affinity chromatography method using a protein A column to obtain a plurality of purified anti-adenovirus monoclonal antibodies.
  • two antibodies 1 and 2 selected in consideration of reactivity and specificity were used from a plurality of obtained anti-adenovirus monoclonal antibodies.
  • Example 2 Immunoassay device for measuring adenovirus 1. Immobilization of anti-adenovirus antibody on nitrocellulose membrane A solution prepared by diluting the anti-adenovirus antibody (antibody 2) prepared in Example 1 with a buffer solution and an anti-mouse IgG antibody were prepared, and nitrocellulose lined with a PET film was prepared. An anti-adenovirus antibody was linearly applied to the sample pad side of the membrane, and an anti-mouse IgG antibody was linearly applied to the absorber side. Then, the nitrocellulose membrane was sufficiently dried under warm air to obtain an anti-adenovirus antibody-immobilized membrane.
  • anti-adenovirus antibody on colored polystyrene particles
  • the anti-adenovirus antibody (antibody 1) prepared in Example 1 was covalently bound to the colored polystyrene particles, and then the colored polystyrene particles were suspended in a suspension. Then, anti-adenovirus antibody-bound colored polystyrene particles were obtained, which were sufficiently dispersed by ultrasonic treatment.
  • the particles obtained here are referred to as anti-adenovirus antibody-immobilized particles.
  • the anti-adenovirus antibody-immobilized particles prepared in step 2 were applied in a predetermined amount to a glass fiber non-woven fabric and sufficiently dried under warm air.
  • the pad obtained here is referred to as a labeled antibody pad.
  • adenovirus test device The anti-adenovirus antibody-immobilized membrane prepared in 1 and the labeled antibody pad prepared in 2 and 3 were bonded to other members (backing sheet, absorption band, sample pad) and cut into a width of 5 mm. , Adenovirus testing device.
  • the immunoassay device using the anti-adenovirus antibody of the present invention reacts with adenovirus but does not show cross-reactivity with other causative viruses of respiratory infections. , It was confirmed that it reacts specifically to adenovirus.
  • the immunoassay device using the anti-adenovirus antibody of the present invention has the highest reactivity to type 2 adenovirus, and is the most reactive to other types of adenovirus as well as kit A. It was confirmed that it had high reactivity.
  • Example 3 Antigen recognition site of anti-adenovirus monoclonal antibody The antigen recognition site of the anti-adenovirus monoclonal antibody obtained in Example 1 was confirmed by western blotting and LC-MS / MS.
  • Adenovirus was infected with A549 cells and cultured. Adenovirus-infected cells were collected on the 7th day of culture, and the cells were disrupted by ultrasonic treatment. Cell residues were removed from the cell disruption solution by centrifugation to obtain an adenovirus concentrate.
  • Sample preparation without reduction treatment A 2-fold dilution series of the adenovirus concentrate obtained in 1 was prepared, and the final concentration was 62.5 mM Tris-HCl (pH 6.5), 10 w / v% glycerol, 2.3 w / v% SDS, Each reagent was added so as to have 0.05% BPB (dye), and routine SDS-PAGE was performed without heat denaturation treatment.
  • the two antibodies (antibody 1 and antibody 2) produced in Example 1 are both proteins (triad of hexone) around 200 kD contained in the sample obtained in 2 (without reduction treatment). It reacted strongly to the body) (left figure). It is considered that the hexone trimer is a monomer by the reduction treatment, and in the sample obtained by 3 (with reduction treatment), a very weak reaction was observed with the protein (hexone monomer) around 100 kD. (Right figure). The results of staining the gel after electrophoresis obtained in 2 and 3 with CBB are shown in FIG.
  • the main protein contained in the sample obtained in 2 is around 200 kD (left figure), and in the sample obtained in 3 (with reduction treatment), 100 to 150 kD. It was (right figure).
  • the amino acid sequence was analyzed by LC-MS / MS after hydrolysis with trypsin.
  • Mascot Ver. 2.5
  • Scaffold Proteome Software
  • both of the two antibodies obtained in Example 1 react more strongly with the hexone trimer protein than with the hexone monomer, and show a weak reaction with the monomeric hexone protein. I found out. Although the reaction between the antibody of the present invention and the hexone monomer is a weak reaction, it has been shown that the antibody of the present invention that reacts with a specific sequence in the monomer by an antigen-antibody reaction is very effective in detecting adenovirus. Was done.
  • Example 4 Analysis of reactivity of anti-adenovirus monoclonal antibody to adenovirus hexon protein by peptide microarray PepStar (manufactured by JPT Peptide Technologies, hereinafter referred to as “Pepstar”) 1. Preparation of PepStar Peptide microarray Pepstar (JPT Peptide Technologies) in which the peptides shown in the peptide library shown in Table 4 are immobilized based on the amino acid sequence information of the type 3 adenovirus GB strain hexone protein (GenBank Accession No. AB330084.1). (Made by the company) was purchased.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/JP2021/015540 2020-04-16 2021-04-15 アデノウイルスの免疫測定方法及び免疫測定器具 Ceased WO2021210632A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US17/919,065 US20230176055A1 (en) 2020-04-16 2021-04-15 Adenovirus immunoassay method and immunoassay instrument
KR1020227035454A KR20220167285A (ko) 2020-04-16 2021-04-15 아데노바이러스의 면역 측정 방법 및 면역 측정 기구
EP21788631.6A EP4116323A4 (en) 2020-04-16 2021-04-15 Adenovirus immunoassay method and immunoassay instrument
CN202180028573.3A CN115362170A (zh) 2020-04-16 2021-04-15 腺病毒的免疫测定方法及免疫测定器具

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020073236A JP7291659B2 (ja) 2020-04-16 2020-04-16 アデノウイルスの免疫測定方法及び免疫測定器具
JP2020-073236 2020-04-16

Publications (1)

Publication Number Publication Date
WO2021210632A1 true WO2021210632A1 (ja) 2021-10-21

Family

ID=78084558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2021/015540 Ceased WO2021210632A1 (ja) 2020-04-16 2021-04-15 アデノウイルスの免疫測定方法及び免疫測定器具

Country Status (7)

Country Link
US (1) US20230176055A1 (https=)
EP (1) EP4116323A4 (https=)
JP (3) JP7291659B2 (https=)
KR (1) KR20220167285A (https=)
CN (1) CN115362170A (https=)
TW (1) TW202204394A (https=)
WO (1) WO2021210632A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116789807A (zh) * 2023-06-14 2023-09-22 珠海重链生物科技有限公司 抗腺病毒单克隆抗体及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120309720B (zh) * 2025-06-11 2025-09-02 北京溯本源和生物科技有限公司 一种用于5型腺病毒特异性检测单克隆抗体的组合及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000290299A (ja) 1999-04-07 2000-10-17 Toagosei Co Ltd モノクローナル抗体及びこれを用いたアデノウイルス検出法
JP2000290298A (ja) 1999-04-06 2000-10-17 Toagosei Co Ltd アデノウイルスに反応するモノクローナル抗体及びこれを用いたアデノウイルス検出法
JP2008122372A (ja) * 2006-10-19 2008-05-29 Denka Seiken Co Ltd 試料ろ過フィルターを用いる簡易メンブレンアッセイ方法及びキット

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794622A (zh) * 2017-05-02 2018-11-13 广州医科大学附属第医院 一种人3型腺病毒的中和性人源化单克隆抗体及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000290298A (ja) 1999-04-06 2000-10-17 Toagosei Co Ltd アデノウイルスに反応するモノクローナル抗体及びこれを用いたアデノウイルス検出法
JP2000290299A (ja) 1999-04-07 2000-10-17 Toagosei Co Ltd モノクローナル抗体及びこれを用いたアデノウイルス検出法
JP2008122372A (ja) * 2006-10-19 2008-05-29 Denka Seiken Co Ltd 試料ろ過フィルターを用いる簡易メンブレンアッセイ方法及びキット

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
DATABASE Nucleotide 14 April 2008 (2008-04-14), ANONYMOUS: "Human adenovirus 3 gene for hexon, complete cds, strain: GB", XP055857576, retrieved from GENBANK Database accession no. AB330084 *
É. ÁDÁM, I. NÁSZ , A. LENGYEL: "Characterization of adenovirus hexons by their epitope composition", ARCHIVES OF VIROLOGY, vol. 141, no. 10, 1 October 1996 (1996-10-01), AT , pages 1891 - 1907, XP009531036, ISSN: 0304-8608, DOI: 10.1007/BF01718202 *
IASR, vol. 38, July 2017 (2017-07-01), pages 133 - 135
KOHLER ET AL.: "Nature", vol. 256, 1975, pages: 495 - 497
MIZUTA K; MATSUZAKI Y; HONGO S; OHMI A; OKAMOTO M; NISHIMURA H; ITAGAKI T; KATSUSHIMA N; OSHITANI H; SUZUKI A; FURUSE Y; NODA M; K: "Stability of the seven hexon hypervariable region sequences of adenovirus types 1-6 isolated in Yamagata, Japan between 1988 and 2007", VIRUS RESEARCH, vol. 140, no. 1-2, 1 March 2009 (2009-03-01), pages 32 - 39, XP025991637, ISSN: 0168-1702, DOI: 10.1016/j.virusres.2008.10.014 *
QIU HONGLING, ZHOU ZHICHAO, FENG KAIXIA, TIAN XINGUI, LI XIAO, LI HAITAO, XING KE, CHEN JINGXIAN, LI CHUANJIANG, ZHOU RONG: "Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type 3", VIRUS RESEARCH, vol. 146, no. 1-2, 1 December 2009 (2009-12-01), pages 58 - 65, XP055857567, DOI: 10.1016/j.virusres.2009.08.011 *
See also references of EP4116323A4
SETO D ET AL., J VIROL, vol. 85, 2011, pages 5701 - 5702
TIAN XINGUI; LI CHENYANG; XUE CHUNYAN; LI XIAO; ZHOU ZHICHAO; ZHOU RONG: "Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3", VIRUS RESEARCH, vol. 177, no. 2, 1 November 2013 (2013-11-01), pages 189 - 193, XP028735780 *
XIAO-HUI YUAN., YING-CHEN WANG., WEN-JING JIN , BIN-BIN ZHAO , CAI-FENG CHEN , JIAN YANG , JING-FEI WANG , YING-YING GUO , JING-JU: "Structure-Based High-Throughput Epitope Analysis of Hexon Proteins in B and C Species Human Adenoviruses (HAdVs)", PLOS ONE, vol. 7, no. 3, e32938, 13 March 2012 (2012-03-13), pages 1 - 13, XP055857578 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116789807A (zh) * 2023-06-14 2023-09-22 珠海重链生物科技有限公司 抗腺病毒单克隆抗体及其应用
CN116789807B (zh) * 2023-06-14 2024-01-16 珠海重链生物科技有限公司 抗腺病毒单克隆抗体及其应用

Also Published As

Publication number Publication date
TW202204394A (zh) 2022-02-01
JP2023052742A (ja) 2023-04-12
JP2024157042A (ja) 2024-11-06
JP7671791B2 (ja) 2025-05-02
JP7804731B2 (ja) 2026-01-22
CN115362170A (zh) 2022-11-18
KR20220167285A (ko) 2022-12-20
EP4116323A1 (en) 2023-01-11
US20230176055A1 (en) 2023-06-08
JP7291659B2 (ja) 2023-06-15
EP4116323A4 (en) 2024-01-24
JP2021168618A (ja) 2021-10-28

Similar Documents

Publication Publication Date Title
JP7804731B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具
JP7455947B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具
JP2021075496A (ja) 抗ｒｓウイルスを認識する抗体、並びに該抗体を用いた免疫測定方法及び免疫測定器具
JP2023126867A (ja) アデノウイルスの免疫測定方法及び免疫測定器具
JP7746495B2 (ja) アデノウイルスの免疫測定方法及び免疫測定器具
JP2023181275A (ja) マイコプラズマ・ニューモニエの免疫測定方法及び免疫測定器具
WO2022244861A1 (ja) 抗ノロウイルス抗体

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21788631

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021788631

Country of ref document: EP

Effective date: 20221006

NENP Non-entry into the national phase

Ref country code: DE